This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
Scores highest PAT of Rs. 118 crore in FY25
This marks yet another milestone in our series of successful audits over the past year
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
Alembic Pharmaceuticals commissions new facility at Pithampur
This approval authorizes the company to export Ibuprofen to the Chinese markets
Subscribe To Our Newsletter & Stay Updated
